News ArticleGlaxoSmithKline Pharmaceuticals Delivers Balanced Double-Digit Growth in Q2 FY27 Across Key Therapeutic Areas Including Specialty Oncology
Company sustains market leadership in paediatric vaccines and expands specialty oncology portfolio impact to approximately 300 patients quarterly
GlaxoSmithKline Pharmaceuticals Limited reported robust financial performance for Q2 FY27, driven by balanced growth across general medicines, paediatric and adult vaccines, and specialty oncology portfolios. The company maintained leadership in pediatric vaccines and expanded market share amid a 14.5% industry growth in India. Specialty products like Nucala, Jemperli, and Zejula impacted nearly 300 patients this quarter.
GlaxoSmithKline Pharmaceuticals Limited
Earnings Call Transcript
GlaxoSmithKline Pharmaceuticals Limited achieved strong double-digit growth in Q2 FY27 with balanced performance across general medicines, vaccines, and specialty oncology segments, aligned with a 14.5% industry growth in India.
The company maintained top-line growth by expanding its established portfolio in India, particularly in general medicines and paediatric vaccines, while accelerating launches of innovative products from its global pipeline.
The Indian pharmaceutical industry grew 14.5% in Q2 FY27, with volume growth alongside price increases and new product introductions. GSK's growth was broad-based across chronic and acute therapy areas, with chronic segments growing 17% and acute segments 13%.
GSK’s flagship brands in general medicines outperformed the market with above 100% evolution index and increased market shares, supported by supply resolution in vaccines despite initial global constraints.
Paediatric vaccines leadership was sustained with gains in flagship brands, while adult vaccination showed growth driven by increased prescribers and data-supported campaigns, notably for shingles prevention linked to cardiovascular event reduction.
Specialty portfolio products such as Nucala, Jemperli, and Zejula, launched within the last 24 months, expanded their impact, treating nearly 300 patients in Q2 FY27, especially in oncology segments like gynaecological malignancies.
Highlights
- Indian pharmaceutical market grew at 14.5% in Q2 FY27 with volume, price, and new introductions contributing.
- GSK’s general medicines brands posted over 100% evolution index, outperforming the market.
- Supply issues in vaccines were resolved within the quarter, maintaining leadership in paediatric vaccines.
- Adult vaccination segment growth driven by increased prescribers and new data-based initiatives.
- Specialty oncology portfolio treated approximately 300 patients in Q2 FY27, marking significant portfolio expansion since launch.
- Multiple new innovative product launches planned over the next 24 to 36 months to sustain growth momentum.
Key Data Snapshot
What happened
- GlaxoSmithKline Pharmaceuticals reported a well-balanced double-digit growth for Q2 FY27 across general medicines, vaccines, and specialty oncology.
- The Indian pharmaceutical market grew by approximately 14.5%, with GSK maintaining growth momentum in line with industry trends.
- GSK’s general medicines brands experienced significant growth with increased market shares backed by strong competitive performance.
Key details
- The company navigated global vaccine supply challenges to serve demand effectively, retaining leadership in paediatric vaccines.
- Adult vaccination showed positive growth through increased prescriber base and data-driven initiatives, such as linking shingles prevention to cardiovascular benefits.
- Specialty oncology products, including Nucala, Jemperli, and Zejula, delivered notable patient impact soon after being launched within the past two years.
Strategic context
- GSK aims to sustain top-line growth by growing its established portfolio in India and accelerating launches of innovative assets over the next 24-36 months.
- The company operates with a three-priority focus: pursuing top-line growth, accelerating new launches, and simplifying operations to remove inefficiencies.
- GSK’s diversified portfolio spans general medicines, vaccines, specialty respiratory, and oncology, enabling balanced growth across segments.
Highlights
- Indian pharmaceutical market grew at 14.5% in Q2 FY27 with volume, price, and new introductions contributing.
- GSK’s general medicines brands posted over 100% evolution index, outperforming the market.
- Supply issues in vaccines were resolved within the quarter, maintaining leadership in paediatric vaccines.
- Adult vaccination segment growth driven by increased prescribers and new data-based initiatives.
- Specialty oncology portfolio treated approximately 300 patients in Q2 FY27, marking significant portfolio expansion since launch.
- Multiple new innovative product launches planned over the next 24 to 36 months to sustain growth momentum.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
More News on Earnings Call Transcript
View allLatest corporate announcements and market updates in Earnings Call Transcript.
Hester Biosciences Posts 28% Revenue Growth and 131% Profit Rise in Q2 FY27 Supported by Poultry Healthcare Expansion
Hester Biosciences Limited reported a 28% increase in standalone revenue to Q2 FY27 and a 131% rise in profit after tax, driven by growth in its poultry healthcare division and enhanced operational efficiencies. Consolidated revenue grew by 38%, primarily due to the India business, while continued investment in manufacturing and renewable energy projects supports future growth.
Read Full Story
Kirloskar Ferrous Industries Limited Posts 16% Revenue Growth to Rs. 2,057 Crores in Q2 FY'27
Kirloskar Ferrous Industries Limited reported a 16% growth in revenue to Rs. 2,057 crores for the quarter ended September 2026, with pig iron and casting segments driving increased sales and production volumes. The company partially recovered from price and supply challenges, providing volume and pricing updates during its Q2 FY'27 earnings call.
Read Full Story
Diamond Power Infrastructure posts INR1,032 crore revenue in Q2 FY27, 135% increase YoY, and INR108 crore PAT
Diamond Power Infrastructure Limited reported a sharp rise in revenue to INR1,032 crores for Q2 FY27, marking a 135% increase over the previous year, supported by strong growth in medium voltage cables, conductors, and new data centre cable production. Profit after tax for the quarter was INR108 crores, nearly four times that of last year.
Read Full Story
